Dr. Cara A. Mathews, MD
OB-GYN (Obstetrics & Gynecology) (Obstetrics & Gynecology Physician)
1 Blackstone Street, 3rd Floor
Providence, RI 02903
Who else practices at this address →
Providence County includes mental health (6% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Geisel School of Medicine at Dartmouth (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 100
Licensed in Connecticut since 2012, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: Geisel School of Medicine at Dartmouth
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Obstetrics & Gynecology Physician primary
RI license MD14046 · CT license 51258 (first issued 2012; active) -
Gynecologic Oncology Physician
CT license 51258 (first issued 2012; active) · RI license MD14046
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: OB-GYN (Obstetrics & Gynecology) per capita by county →
Where they work
Hospitals
- The Miriam Hospital Providence, RI
- Rhode Island Hospital Providence, RI
- Lawrence & Memorial Hospital New London, CT
- Kent County Memorial Hospital Warwick, RI
- Women & Infants Hospital of Rhode Island Providence, RI
Medical groups
- Affinity Physicians LLC. (730 clinicians)
- Wih Faculty Physicians, Inc (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 100
- Services billed
- 337
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 95 | 49 |
| Established patient office or other outpatient visit, 20-29 minutes | 53 | 36 |
| Established patient office or other outpatient visit, 40-54 minutes | 18 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Providence, RI | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 5 payments worth $5,078 in total to this clinician.
| Daiichi Sankyo Inc. | $3,408 |
|---|---|
| GlaxoSmithKline, LLC. | $1,670 |
| Consulting Fee | $4,800 |
|---|---|
| Travel and Lodging | $278 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Daiichi Sankyo Inc. Mar 5, 2025 | Consulting Fee | $1,938 |
| GlaxoSmithKline, LLC. Feb 12, 2025 | Consulting Fee | $1,392 |
| Daiichi Sankyo Inc. Dec 22, 2025 | Consulting Fee Enhertu · ONCOLOGY | $735 |
| Daiichi Sankyo Inc. Dec 22, 2025 | Consulting Fee Enhertu · ONCOLOGY | $735 |
| GlaxoSmithKline, LLC. Feb 12, 2025 | Travel and Lodging travel to CATALONIA, Spain | $278 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 6 companies. The companies reported $409,325 in research payments for these studies, mostly to the institutions running them.
- Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors
Genmab U.S., Inc. - A phase 3, randomized, double-blind, multicenter study of dostarlimab
GlaxoSmithKline, LLC. - Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
AbbVie Inc. · Active, not recruiting · NCT05456685 - Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers
AbbVie Inc. · Completed · NCT05041257 - Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
Aadi Bioscience, Inc. · Recruiting · NCT05997017 - A phase 1 dose escalation and cohort expansion study of TSR-042, an an
GlaxoSmithKline, LLC. - A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer.
Genmab U.S., Inc. - A Modular Phase IIIa OpenLabel Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination with Anticancer Agents in Pati…
AstraZeneca Pharmaceuticals LP - First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
AbbVie Inc. · Active, not recruiting · NCT05527184 - A Multicenter Phase 1 Open-label Dose-escalation and Expansion Study of TNB-383B a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.